BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 6260197)

  • 1. Effects of divalent metals on the specificity of inhibitors of the cyclic nucleotide phosphodiesterases from bovine heart.
    Donnelly TE; Barron B
    Biochim Biophys Acta; 1981 Jan; 657(1):168-78. PubMed ID: 6260197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form.
    Lavan BE; Lakey T; Houslay MD
    Biochem Pharmacol; 1989 Nov; 38(22):4123-36. PubMed ID: 2480793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effect of regucalcin on Ca2+/calmodulin-dependent cyclic AMP phosphodiesterase activity in rat kidney cytosol.
    Yamaguchi M; Kurota H
    Mol Cell Biochem; 1997 Dec; 177(1-2):209-14. PubMed ID: 9450664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological inhibition of calmodulin-sensitive phosphodiesterases.
    Ilien B; Ruckstuhl M; Landry Y
    J Pharmacol; 1982; 13(2):307-16. PubMed ID: 6285085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective alteration of Ca2+-dependent and Ca2+-independent cyclic nucleotide phosphodiesterase activity in rat cerebral cortex by cyclic nucleotides and their analogs.
    Davis CW
    Biochim Biophys Acta; 1982 Jul; 705(1):1-7. PubMed ID: 6288105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the soluble cyclic nucleotide phosphodiesterases in Xenopus laevis oocytes. Evidence for a calmodulin-dependent enzyme.
    Miot F; Erneux C
    Biochim Biophys Acta; 1982 Feb; 701(2):253-9. PubMed ID: 6280770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
    Price B; Pyne NJ; Houslay MD
    Biochem Pharmacol; 1987 Dec; 36(23):4047-54. PubMed ID: 2825712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Separation and investigation of the regulatory properties of two forms of cyclic nucleotide phosphodiesterase from rabbit heart--sensitive and insensitive to Ca-dependent regulator protein].
    Tkachuk VA; Lazarevich VG; Men'shikov MIu; Severin SE
    Biokhimiia; 1978 Sep; 43(9):1622-30. PubMed ID: 214170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Properties of the activator-dependent cyclic nucleotide phosphodiesterase from bovine heart.
    Donnelly TE
    Biochim Biophys Acta; 1977 Jan; 480(1):194-203. PubMed ID: 188479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of cyclic AMP and cyclic GMP phosphodiesterases of cardiac nuclear fraction.
    Ahluwalia GS; Rhoads AR
    Biochem Pharmacol; 1982 Mar; 31(5):665-9. PubMed ID: 6177320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic nucleotide phosphodiesterase in heart and aorta of spontaneously hypertensive rats.
    Sharma RV; Bhalla RC
    Biochim Biophys Acta; 1978 Oct; 526(2):479-88. PubMed ID: 214127
    [No Abstract]   [Full Text] [Related]  

  • 12. Cyclic nucleotide analogs used to study phosphodiesterase catalytic and allosteric sites.
    Erneux C; Miot F
    Methods Enzymol; 1988; 159():520-30. PubMed ID: 2842616
    [No Abstract]   [Full Text] [Related]  

  • 13. The metabolism of cyclic nucleotides in the guinea-pig pancreas. Cyclic AMP phosphodiesterase and cyclic GMP phosphodiesterase.
    Methven P; Lemon M; Bhoola K
    Biochem J; 1980 Feb; 186(2):491-8. PubMed ID: 6246887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
    Marcoz P; Prigent AF; Lagarde M; Nemoz G
    Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.
    Souness JE; Diocee BK; Martin W; Moodie SA
    Biochem J; 1990 Feb; 266(1):127-32. PubMed ID: 2155604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myofibrillar bound cyclic nucleotide phosphodiesterase in heart and skeletal muscle.
    Worby A; Mensah LM; Murray KJ
    Biochem Soc Trans; 1992 May; 20(2):129S. PubMed ID: 1327896
    [No Abstract]   [Full Text] [Related]  

  • 17. Differential recognition of calmodulin-enzyme complexes by a conformation-specific anti-calmodulin monoclonal antibody.
    Hansen RS; Beavo JA
    J Biol Chem; 1986 Nov; 261(31):14636-45. PubMed ID: 3021748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 19. [Modern representations of multiple forms of cyclic nucleotide phosphodiesterases in mammalian tissues].
    Medvedeva MV
    Biokhimiia; 1995 Mar; 60(3):364-86. PubMed ID: 7734612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative kinetic study of bovine calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes utilizing cAMP, cGMP and their 2'-O-anthraniloyl-,2'-O-(N-methylanthraniloyl)-derivatives as substrates.
    Grewal J; Karuppiah N; Mutus B
    Biochem Int; 1989 Dec; 19(6):1287-95. PubMed ID: 2561449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.